Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 10, 2006, Pages 1544-1554

  González Cuevas, Jaime ^a   Bueno Topete, Miriam ^a   Armendariz Borunda, Juan ^a,b  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b OPD Civil Hospital Juan I Menchaca   (Mexico)

Author keywords

Carbon tetrachloride; Cirrhosis; Collagens; Hepatic stellate cells; Metalloproteinases; Urokinase plasminogen activator

Indexed keywords

ADENOVIRUS VECTOR; COLLAGEN TYPE 1; GELATINASE A; GELATINASE B; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; EVALUATION; GENETIC TRANSFECTION; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STELLATE CELL; SUPERNATANT; TISSUE CULTURE; TISSUE SLICE; WESTERN BLOTTING;

EID: 33747602999     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04398.x     Document Type: Article

References (46)

1. Chief Medical Officer. Annual Report of the Chief Medical Officer 2001. Liver Cirrhosis: Starting to Strike at Younger Ages. USA: Department of Health, 2001. Available from: http://www.doh.gov.uk/cmo/annual [Accessed April 2001] report 2001/livercirrhosis.htm
2. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are going? Gut 2002; 50: 585-5.
3. Friedman SL. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N. Engl. J. Med. 1993; 328: 1828-35.
4. Darras V. Measurement of urokinase-type plasminogen activator (u-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies. Thromb. Haemost. 1986; 56: 411-14.
5. Leyland H, Gentry J, Arthur M, Benyon R. The plasminogen-activating system in hepatic stellate cells. Hepatology 1996; 24: 1172-8.
6. Way-yee LI, Chong SSN, Huang EY, Tuan T-L. Plasminogen activator/plasmin system: a major player in wound healing? Wound Repair Regen. 2003; 11: 239-47.
7. Salgado S, Garcia J, Vera J et al. Cirrosis is reverted by urokinase-type plasminogen activator gene therapy. Mol. Ther. 2000; 2: 545-51.
8. Miranda-Diaz A, Rincon AR, Salgado S et al. Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis. Mol. Ther. 2004; 9: 30-7.
9. Choong P, Faorth A, Nadesapillai A. Urokinase plasminogen activator system. Clin. Orthop. 2003; 415S: S46-S48.
10. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 2004; 25: 450-6.
11. Carmeliet P, Schoonjans L, Kieckens L et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-24.
12. Carmeliet P, Bouche A, De Clerq C et al. Biological effects of disruption of the tissue type plasminogen activator, urokinase-type plasminogen activator, and plasminogen activator inhibitor-1 genes in mice. Ann. N.Y. Acad. Sci. 1995; 748: 367-81.
13. Bezerra JA, Currier AR, Melin-Aldana H et al. Plasminogen activators direct reorganization of the liver lobule after acute injure. Am. J. Pathol. 2001; 158: 921-9.
14. Pérez-Liz G, Flores-Hernández J, Arias-Montaño JA, Reyes-Esparza JA, Rodríguez-Fragozo L. Modulation of urokinase-type plasminogen activator by transforming growth factor beta1 in acetaldehyde-activated hepatic stellate cells.. Pharmacology 2005; 73: 23-30.
15. Armendàriz-Borunda J, Seyer JM, Kang AH, Raghow R. Regulation of TGFβ gene expression in rat liver intoxicated with carbon tetrachloride. FASEB J. 1990; 4: 215-21.
16. 3H) hydroxyproline in liver slices of CCL4 cirrhotic rats. Lab. Invest. 1987; 57: 392.
17. Sambrook J, Fritsch EF, Maniatis T, eds. Molecular Cloning: A Laboratory Manual, 2nd edn. New York: Cold Spring Harbor Laboratory Press, 1989.
18. Bradford MM. A rapid and sensitive method for the quantitation of proteing utilizing the principle of protein-dye binding. Annal. Biochem. 1976; 72: 248-54.
19. Monvosin A, Neaud V, De Ledinghen V et al. Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J. Hepatol. 1999; 30: 511-18.
20. Higazi A-R, Mayer M. In vitro inhibition of urokinase by penicicillins. Thromb. Haemost. 1988; 60: 305-7.
21. Chain Ernest B. The Chemical Structure of the Penicillins. Nobel Lecture, March 20, 1946. Available from: http://nobelprize.org/medicine/laureates/1945/ chain-lecture.pdf [Accessed March 2000].
22. Lieber A, Vrancken PM-J, Gown A, Perkins J, Kay MA. A modified urokinase plasminogen activator induces liver regeneration without bleeding. Hum. Gene Ther. 1995; 6: 1029-37.
23. Nyberg-Hoffman C, Shabram P, Li W, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat. Med. 1997; 3: 808-11.
24. Kenagy RD, Nikkari ST, Welgus HG, Clowes AW. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smoth muscle cells. J. Clin. Invest. 1994; 93: 1987-93.
25. Roche PC, Campeau JD, Shaw STJ. Comparative electrophoretic analysis of human and plasminogen activators in SDS polyacrylamide gels containing plasminogen and casein. Biochim. Biophys. Acta 1983; 745: 82-9.
26. Chommczynsky P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol cloroform extration. Annal. Biochem. 1987; 162: 156-9.
27. Delgado RV, Salazar A, Panduro A, Armendariz-Borunda J. Treatment with anti-transforming growth factor b antibodies influences an altered pattern of cytokines expresion in injured rat liver. Biochim. Biophys. Acta 1998; 1442: 20-7.
28. Bueno MR, Daneri A, Armendariz-Borunda J. Cholestasis-induced fibrosis is reduced by interferon α-2a and is associated with elevated liver metalloprotease activity. J. Hepatol. 2000; 33: 915-25.
29. Sancho-Bru P, Bataller R, Gasull X et al. Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. J. Hepatol. 2005; 43: 272-82.
30. Czuwara J, Sementchenko V, Watson D, Trojanowska M. Ets-1 is an effector of the transforming growth factor β (TGFβ) signaling pathway and an antagonist of the profibrotic effects of TGFβ. J. Biol. Chem. 2002; 277: 20 399-498.
31. Reuninig U, Guerrini L, Nishiguchi T et al. Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells. Eur. J. Biochem. 1999; 259: 143-8.
32. Kossakowska A, Lee S, Urbanski L et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am. J. Pathol. 1998; 153: 1895-902.
33. Zhou X, Murphy FR, Gehdu N, Zhang J, Iredale JP, Benyon C. Engagement of a b integrin regulates proliferation and apoptosis of hepatic stellate cells. J. Biol. Chem. 2004; 279: 23 996-4006.
34. Von Bredow DC, Crees AE, Howard EW, Bowden GT, Nagle RB. Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin. Biochem. J. 1998; 331: 965-72.
35. Weiskirchen R, Kneifel J, Weiskirchen S et al. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease. Biol. Chem. Hoppe Seyler 1995; 376: 345-55.
36. Knittel T, Aurisch S, Neubauer K, Eichhorst S, Ramadori G. Cell type specific expression of neural cell adhesion molecule (N-CAM) in ITO cells of rat liver: upregulation during in vitro activation and in hepatic tissue repair. Am. J. Pathol. 1996; 149: 449-62.
37. Myahara T, Schrum L, Rippem R et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J. Biol. Chem. 1999; 275: 35 715-22.
38. Lijnen HR, Arza B, Van Hoef B, Collen D, Declerck P. Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). J. Biol. Chem. 2000; 276: 37645-50.
39. Siller-Lopez F, Sandoval A, Salgado S et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 2004; 126: 1122-33.
40. Powell DW, Mifflin RC, Valentich JD et al. Paracrine cells important in health and disease. Am. J. Physiol. 1999; 277: 1-19.
41. Sawdey M, Podor JT, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. J. Biol. Chem. 1989; 264: 10 396-401.
42. Smith AN, Carter QL, Kniss DA, Brown TL. Characterization of TGFbeta-responsive human trophoblast derived cell line. Placenta 2001; 22: 425-31.
43. Rangaswami H, Bulbule A, Kundu G. Nuclear factor inducing kinase plays a crucial role in osteopontin-induced MAPK/I kinase-dependent nuclear factor kB-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem. 2004; 279: 38 921-35.
44. Dubois B, Massure S, Hurtenbach U et al. Resistance of young gelatinase B-deficent mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 1999; 104: 1507-15.
45. Houde M, de Bruyne G, Bracke M et al. Differential regulation of gelatinase B and tissue-type plasmin activator expression in human bowes melanoma cells. Int. J. Cancer 1993; 1: 395-400.
46. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley James P. Activation of metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 1999; 274: 13 066-76.